Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue	369K -
gross profit	-369K -
selling and marketing expenses
general and administrative expenses		11.04M -	15.29M 38.47%	9.95M 34.95%
selling general and administrative expenses	5.94M -	11.04M 86.00%	15.29M 38.47%	9.95M 34.95%	20.64M 107.51%
research and development expenses	18.44M -	31.44M 70.49%	35.57M 13.13%	35.46M 0.31%	34.19M 3.56%
other expenses		-29.88M -	-41.95M 40.39%	-196.25M 367.87%
cost and expenses	24.75M -	40.75M 64.68%	50.27M 23.35%	44.39M 11.70%	54.83M 23.53%
operating expenses	24.38M -	40.75M 67.17%	50.27M 23.35%	44.39M 11.70%	54.83M 23.53%
interest expense	46K -	72K 56.52%	83K 15.28%	93K 12.05%	150K 61.29%
ebitda	-24.38M -	-73.48M 201.39%	-91.07M 23.95%	-239.44M 162.91%	-54.83M 77.10%
operating income	-24.75M -	-74.08M 199.36%	-91.75M 23.85%	-240.21M 161.81%	-54.83M 77.17%
depreciation and amortization	369K -	609K 65.04%	681K 11.82%	775K 13.80%
total other income expenses net	-21.00M -	-30.63M 45.82%	-44.91M 46.63%	-196.76M 338.14%	-117.76M 40.15%
income before tax	-45.75M -	-74.91M 63.72%	-94.80M 26.55%	-240.81M 154.03%	-172.59M 28.33%
income tax expense	153K -	-85K 155.56%	1K 101.18%	1K 0%	10K 900%
net income	-45.91M -	-74.82M 62.99%	-94.80M 26.70%	-240.81M 154.03%	-172.60M 28.33%
weighted average shs out	86.80M -	86.80M 0%	86.80M 0%	86.80M 0%	74.40M 14.29%
weighted average shs out dil	86.80M -	86.80M 0%	86.80M 0%	86.80M 0%	74.40M 14.29%
eps	-0.53 -	-0.86 62.26%	-1.09 26.74%	-2.77 154.13%	-2.32 16.25%
epsdiluted	-0.53 -	-0.86 62.26%	-1.09 26.74%	-2.77 154.13%	-2.32 16.25%

NASDAQ:APLM

Apollomics, Inc.

Last Close

0.21

26/07 20:00

Market Cap

21.11M

Beta: 1.39

Volume Today

1.85M

Avg: 3.76M

PE Ratio

−0.26

PFCF: −1.48

Preview